Karyopharm Q2 FY26 net loss widens to $67 million; revenue falls 11.85% to $33.4 million

Reuters2026/08/13 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Karyopharm posted Q2 revenue of USD 33.4 million, down 11.86% from a year earlier.
Net loss widened to USD 67 million, or USD 2.32 per share, from USD 37.3 million a year earlier.
U.S. XPOVIO net product revenue rose to USD 30.8 million from USD 29.7 million; royalty revenue climbed to USD 2.5 million from USD 1.6 million.
License and other revenue fell to USD 2.6 million from USD 8.2 million, tied to lower Menarini development-related reimbursement.
Maintained 2026 revenue guidance of USD 130 million-USD 150 million; August sNDA filing for selinexor with ruxolitinib remains on track.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608130730PR_NEWS_USPR_____NE25569) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Karyopharm Q2 FY26 net loss widens to $67 million; revenue falls 11.85% to $33.4 million

You may also like

Crypto prices